CT P25

Drug Profile

CT P25

Alternative Names: Influenza vaccine - Celltrion

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator Celltrion
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 16 Mar 2016 Preclinical development is ongoing in South Korea (Celltrion pipeline, March 2016)
  • 30 Sep 2012 Preclinical trials in Influenza virus infections in South Korea (Parenteral) before September 2102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top